Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-995-0900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees13
OptionableNot Optionable
Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions
What is Aileron Therapeutics' stock symbol?
Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."
How were Aileron Therapeutics' earnings last quarter?
Aileron Therapeutics Inc (NASDAQ:ALRN) posted its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.50) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.58) by $0.08. View Aileron Therapeutics' Earnings History.
When is Aileron Therapeutics' next earnings date?
Has Aileron Therapeutics been receiving favorable news coverage?
News articles about ALRN stock have been trending very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aileron Therapeutics earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are some of Aileron Therapeutics' key competitors?
Some companies that are related to Aileron Therapeutics include CTI BioPharma (CTIC), Infinity Pharmaceuticals (INFI), Avenue Therapeutics (ATXI), KemPharm (KMPH), Synergy Pharmaceuticals (SGYP), Tetraphase Pharmaceuticals (TTPH), Zynerba Pharmaceuticals (ZYNE), Immune Design (IMDZ), Merrimack Pharmaceuticals (MACK), Scpharmaceuticals (SCPH), Fortress Biotech (FBIO), Sienna Biopharmaceuticals (SNNA), Otonomy (OTIC), BIOLINERX LTD/S (BLRX) and Neos Therapeutics (NEOS).
Who are Aileron Therapeutics' key executives?
Aileron Therapeutics' management team includes the folowing people:
- Dr. Manuel C. Aivado, Pres, CEO & Director (Age 49)
- Mr. Donald V. Dougherty CPA, CFA, Sr. VP & CFO (Age 60)
- Ms. Kira A. Nelson CPA, VP of Fin. & Operations (Age 50)
- Dr. D. Allen Annis, Sr. VP of Research
- Dr. Vojislav Vukovic, Chief Medical Officer
When did Aileron Therapeutics IPO?
(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
How do I buy shares of Aileron Therapeutics?
Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aileron Therapeutics' stock price today?
One share of ALRN stock can currently be purchased for approximately $1.23.
How big of a company is Aileron Therapeutics?
Aileron Therapeutics has a market capitalization of $18.14 million. The company earns $-22,600,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Aileron Therapeutics employs 13 workers across the globe.
What is Aileron Therapeutics' official website?
How can I contact Aileron Therapeutics?
Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]
MarketBeat Community Rating for Aileron Therapeutics (NASDAQ ALRN)
MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe ALRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
